Related Experiment Video
Updated: Jan 11, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
The interleukin-6 connection: Understanding cytomegalovirus reactivation following CAR-T-cell therapy
Linghao Li1,2, Zihao Wang1,2, Chongsheng Qian1,2
1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
None:
Of 84 patients with acute lymphoblastic leukaemia, non-Hodgkin lymphoma or multiple myeloma, 22 developed cytomegalovirus (CMV) viraemia following chimeric antigen receptor modified T (CAR-T) cell therapy, resulting in a proportion of 26% and a median time to reactivation of 15.5 days. Sustained high level of interleukin-6 (IL-6) is a significant risk factor for CMV reactivation without significant interaction across subgroups of diagnosis and target. Other risk factors include ≥3 grade cytokine release syndrome (CRS), B-cell maturation antigen (BCMA)-directed CAR and high-dose corticosteroids. Excessive IL-6 during CRS play an important role in the frequent CMV reactivation following CAR-T-cell immunotherapy.
More Related Videos
06:03Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
Published on: September 20, 2024
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy